Final positive readout for primary and several secondary endpoints presented by Federico Cappuzzo, MD, PhD, on October 25, ...
Ensemble will manage its revenue cycle across hospital and physician services as one coordinated operation, from scheduling and registration through coding, billing, and final payment. Grady will ...
On October 26, 2026, Shanghai Henlius Biotech, Inc ("Henlius"), a global, innovation-driven biopharmaceutical company, announced at ...
Shanghai Henlius Biotech, Inc. announced positive results from ASTRIDE, a randomized, descriptive, open-label, U.S. study of serplulimab (in Europe, Hetronifly®), an anti-PD-1 monoclonal antibody (mAb ...
The global stem cell banking market is experiencing robust compound annual growth rate (CAGR) expansion, driven by escalating demand-side dynamics, rising awareness of regenerative medicine ...
Enterome SA, a clinical-stage company pioneering OncoMimics™, a new class of off-the-shelf, multi-targeted in vivo immune therapies, today announced final data from the Phase 1/2 AUDREY study of ...
T-Cell Engager Therapeutics Market to grow from USD 7.2 Bn in 2026 to USD 39.4 Bn by 2036 at a 18.5% CAGR. Get segment, region & competitor insights.
Solid Biosciences Inc. announced that seven abstracts have been accepted for poster presentation at the 33rd European Society of Gene & Cell Therapy (ESGCT) Annual Congress, taking place October 27-30 ...
Add vitamin C to the culture medium for cells. From this, a connection has emerged between technology that alters cell ...
At 160 mg, the confirmed response rate was 43%; at 240 mg, median progression-free survival was 16.0 months. Phase 3 ALPACCA ...
FDA-approved Casgevy and Lyfgenia show high success but cost $2.2-3.1M, involve yearlong treatment, and have limited, uneven ...
SpudCells may one day produce new medicines and materials. But first scientists have to improve them — and make sure they aren’t misused.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results